Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

July 3, 2024

Cybrexa Therapeutics taps Maraganore as strategic advisor

New Haven clinical-stage oncology biotech company Cybrexa Therapeutics announced that John Maraganore has been hired as a strategic advisor to the executive leadership team.

In this role, Maraganore will provide strategic guidance and leverage his experience in the biotech industry to support the advancement of Cybrexa’s peptide drug conjugate, into Phase 2 ovarian cancer clinical trials.

Maraganore served as the founding CEO and a director of Alnylam Pharmaceuticals from 2002 to 2021, where he spearheaded the company’s growth from early-stage RNA interference research to the global approval and commercialization of their first four RNAi therapeutics. 
Under his leadership, Alnylam’s market capitalization value reached $25 billion.
 

Sign up for Enews

0 Comments

Order a PDF